Travoprost monotherapy effective for POAG

October 22, 2014

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

In a 5-year study reported in the Journal of Glaucoma, 36 previously untreated POAG patients received topical travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories), once in the evening in both eyes.

All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.

In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:

  • 16.8 (±2.4) mmHg at the 1-year assessment, a 28.4% decrease in IOP from baseline.
  • 16.8 (±2.5) mmHg at the 2-year assessment (-28.1% from baseline)
  • 16.8 (±2.4) mmHg at the 3-year assessment (-28.5% from baseline)

  • 16.7 (±2.5) mmHg at the 4-year assessment (-28.6% from baseline)
  • 16.9 (±2.4) mmHg at the 5-year assessment (-27.8% from baseline)

To read an abstract of the study, click here.